Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a sell rating to a hold rating in a report issued on Sunday morning.

Several other analysts also recently weighed in on the company. Barclays set a $125.00 target price on Monopar Therapeutics and gave the company an “overweight” rating in a research note on Monday, October 13th. BTIG Research increased their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Chardan Capital boosted their target price on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Sunday, November 9th. Raymond James Financial downgraded shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their price target for the company from $142.00 to $123.00 in a report on Friday, November 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $106.20.

Monopar Therapeutics Trading Down 3.2%

NASDAQ MNPR opened at $74.61 on Friday. Monopar Therapeutics has a 1 year low of $21.00 and a 1 year high of $105.00. The company has a fifty day simple moving average of $84.16 and a 200 day simple moving average of $57.73. The company has a market cap of $498.39 million, a P/E ratio of -21.69 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Equities research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the transaction, the insider directly owned 272,026 shares of the company’s stock, valued at approximately $17,303,573.86. This represents a 66.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter worth about $34,000. AlphaQuest LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth about $44,000. BNP Paribas Financial Markets lifted its holdings in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.